In March 2020, a research letter published in The Lancet suggested that patients with hypertension, heart disease or diabetes who were on renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), might be at greater risk of severe disease with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (1). Here, ACE is linked to diabetes mellitus.